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Abstract
Observational studies suggest that higher birth weight (BW) is associated with increased risk of breast cancer in adult life. We 
conducted a two-sample Mendelian randomisation (MR) study to assess whether this association is causal. Sixty independ-
ent single nucleotide polymorphisms (SNPs) known to be associated at P < 5 × 10−8 with BW were used to construct (1) a 
41-SNP instrumental variable (IV) for univariable MR after removing SNPs with pleiotropic associations with other breast 
cancer risk factors and (2) a 49-SNP IV for multivariable MR after filtering SNPs for data availability. BW predicted by the 
41-SNP IV was not associated with overall breast cancer risk in inverse-variance weighted (IVW) univariable MR analysis of 
genetic association data from 122,977 breast cancer cases and 105,974 controls (odds ratio = 0.86 per 500 g higher BW; 95% 
confidence interval 0.73–1.01). Sensitivity analyses using four alternative methods and three alternative IVs, including an 
IV with 59 of the 60 BW-associated SNPs, yielded similar results. Multivariable MR adjusting for the effects of the 49-SNP 
IV on birth length, adult height, adult body mass index, age at menarche, and age at menopause using IVW and MR-Egger 
methods provided estimates consistent with univariable analyses. Results were also similar when all analyses were repeated 
after restricting to estrogen receptor-positive or -negative breast cancer cases. Point estimates of the odds ratios from most 
analyses performed indicated an inverse relationship between genetically-predicted BW and breast cancer, but we are unable 
to rule out an association between the non-genetically-determined component of BW and breast cancer. Thus, genetically-
predicted higher BW was not associated with an increased risk of breast cancer in adult life in our MR study.
Keywords Birth weight · Breast cancer · Mendelian randomisation
Background
The hypothesis that the risk of developing breast cancer 
in adulthood may be increased by factors that first act in 
utero—in particular by fetal exposure to higher levels of 
maternal estrogen—was first proposed in 1990 [1]. Since 
then, several observational studies have examined this 
hypothesis by using birth weight as an index of the effects 
of intrauterine hormones on fetal growth and of the extent of 
the fetal mammary stem cell pool from which breast tumours 
may eventually arise [2–6]. When considered overall, these 
studies have suggested that higher weight at birth may be 
associated with an increased susceptibility to breast cancer 
in later life [7–20], but a few studies have failed to dem-
onstrate this association [21–28]. While most studies have 
adjusted for the effects of recognised breast cancer risk fac-
tors measured at a specific time point in their samples, this 
does not rule out the possibility of residual effects of these 
factors, which may act at different points over the course of 
life, driving the observed association between birth weight 
and breast cancer. It has not been possible to determine 
whether this association is causal and to dissect whether 
it is birth weight per se or an external factor influencing 
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fetal growth and development that might underpin a possible 
association with future breast cancer risk.
Mendelian randomisation (MR) is a form of instrumental 
variable (IV) analysis that uses genetic instruments or single 
nucleotide polymorphisms (SNPs) associated with an expo-
sure of interest to infer a causal relationship (or lack thereof) 
between this exposure and an outcome. Since SNPs are ran-
domly allocated at conception, an MR study may be thought 
of as being analogous to a randomised controlled trial of 
the effects of the exposure on the outcome, making such a 
study less susceptible to classical confounding. However, 
MR is a valid tool for causal inference only if three assump-
tions hold: (1) SNPs used as part of the IV are associated 
with the exposure, (2) these SNPs are not associated with 
known or unknown confounders for the outcome, and (3) 
given these confounders, the SNPs affect the outcome only 
through the exposure of interest and not via other pathways. 
Here, we report the result of an MR analysis that aimed 
to investigate the relationship between birth weight as the 
exposure and susceptibility to breast cancer as the outcome. 
A genome-wide association meta-analysis of over 150,000 
individuals has previously identified 60 independent SNP 
loci that are associated with birth weight (BW) and genetic 
association data for 59 of these loci are available from a 
separate meta-analysis of breast cancer susceptibility that 
included over 225,000 women [29, 30]. We used these data 
to perform an MR study with a two-sample design (Fig. 1) 
wherein the genetic associations with outcome and exposure 
are estimated in independent studies. It is challenging to 
evaluate empirically whether the assumptions required for 
causal inference with MR are met and therefore, we also 
report the results of several additional analyses performed 
to assess the robustness of our MR result.
Methods
Birth weight (exposure) data
Genome-wide significant (P < 5 × 10−8) associations for 
BW at 60 independent loci were previously reported by 
Horikoshi et al. [29]. The lead SNPs at 49 loci were iden-
tified at P < 5 × 10−8 in the European ancestry component 
(n = 143,677) of the study by Horikoshi et al. The lead SNPs 
at the remaining loci had P values ranging from 5.1 × 10−8 to 
4.4 × 10−7 in the European ancestry meta-analysis and were 
identified at P < 5 × 10−8 in the trans-ancestry component of 
the same study, which combined the European results with 
results from 10,104 individuals of diverse ancestry [29]. 
Summary results from the European-only meta-analysis for 
all 60 SNPs were obtained from the Early Growth Genetics 
(EGG) Consortium (Supplementary Tables 1 and 2). BW in 
the EGG Consortium studies was collected from heterogene-
ous sources (from measurements made at birth by medical 
doctors, birth records and medical registers, maternal inter-
views, and adult self-report) [29].
Breast cancer (outcome) data
Summary results from genome-wide association meta-anal-
yses for breast cancer susceptibility in women of European 
ancestry by Michailidou et al. [30] were downloaded from 
Fig. 1  Schematic overview of study design. BW = birth weight; BMI = body mass index; MR = Mendelian randomisation; IVW = inverse-vari-
ance weighted method; SNP = single nucleotide polymorphism; ER = estrogen receptor; IV = instrumental variable
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the Breast Cancer Association Consortium (BCAC) web-
site (Supplementary Table 1). Results were available for 
59 of the 60 BW-associated lead SNPs (not available for 
rs139975827) for three breast cancer susceptibility pheno-
types (Supplementary Table 2): overall breast cancer risk 
(122,977 cases/105,974 controls), estrogen receptor (ER)-
positive breast cancer risk (69,501 cases/105,974 controls), 
and ER-negative breast cancer risk (21,468 cases/105,974 
controls). No proxy SNPs correlated with rs139975827 
with r2 > 0.8 could be identified. Fifty-eight SNPs were 
either genotyped or imputed with quality score > 0.8 in the 
OncoArray project, which was the largest single component 
of the BCAC meta-analyses [30]. One SNP, rs138715366, 
was imputed with quality score = 0.62 and also retained for 
subsequent analyses.
Birth length and other breast cancer‑risk factor data
Summary results from genome-wide association meta-
analyses for birth length (n = 28,459) [31], adult height 
(n = 253,288) [32], adult body mass index (BMI) (in women; 
n = 171,977) [33], age at menarche (n = 132,989) [34], age 
at menopause (n = 69,360) [35], age at first birth (in women; 
n = 189,656) [36], and number of children ever born (in 
women; n = 225,230) [36] were obtained from four genetic 
consortia. The consortia and corresponding websites used 
for data download are listed in Supplementary Table 1. The 
age at menarche sample used here excluded women geno-
typed in the Collaborative Oncological Gene-environment 
Study (COGS) who were included in the breast cancer meta-
analyses [30, 34]. All summary statistics obtained were from 
analyses limited to individuals of European ancestry. These 
statistics included standardised regression (beta) coefficients 
and P-values from genetic association analysis in each data 
set, with the exceptions of age at first birth and number of 
children ever born, where only P values were available.
Data harmonisation
The genetic association data for BW and breast cancer 
susceptibility were based on imputation using the 1000 
Genomes reference panel, while all other data sets had been 
imputed using HapMap. Out of the 59 BW-associated lead 
SNPs that were also present in the breast cancer data set, 
summary statistics were available for 26 SNPs across all data 
sets (Supplementary Table 3). For an additional 26 SNPs, 
proxy SNPs in linkage disequilibrium with the BW-associ-
ated lead SNP (r2 > 0.6 in European samples) were previ-
ously identified by Horikoshi et al. [29]. The same prox-
ies were used here because they were available across all 
data sets (Supplementary Table 3). For a further two SNPs 
(rs10402712 and rs7402982), proxies with r2 > 0.6 in Euro-
pean samples (rs11667352 and rs2017500, respectively) 
were identified in the current study using the SNP Anno-
tation and Proxy (SNAP) Search tool version 2.2 (http://
archi ve.broad insti tute.org/mpg/snap; [37]). No suitable 
proxy SNP was identified for four BW-associated lead SNPs 
(rs61830764, rs138715366, rs72851023, and rs144843919). 
A fifth SNP (rs11096402) is an X-chromosome variant 
mapped only in the BW and breast cancer data sets.
In summary, breast cancer data were available for 59 of 
the 60 BW-associated lead SNPs. When considering these 
two data sets together with the seven additional “risk fac-
tor” data sets, 54 BW loci had results listed across all data 
sets [26 represented by BW-associated lead SNPs and 28 
by correlated (r2 > 0.6) proxy SNPs]. The signs of the beta 
coefficients for each SNP across all summary data sets were 
aligned to the BW-increasing allele (except for age at first 
birth and number of children ever born, where only P-values 
were available).
Univariable Mendelian randomisation
Of the 54 BW loci represented across all data sets, 13 dem-
onstrated association with at least one of the seven breast 
cancer risk factors at P < 5 × 10−8 (Supplementary Table 3). 
The BW-associated lead SNP at the 41 loci that did not show 
genome-wide significant pleiotropic associations were used 
to construct the main 41-SNP IV for univariable MR analy-
ses (these SNPs are highlighted in Supplementary Table 2). 
This was done to ensure that the univariable MR analyses 
were, as far as possible, evaluating the association between 
BW and adult breast cancer risk independent of the effects 
of SNPs that were also associated with other potential later-
life breast cancer risk factors such as adult height. MR was 
first performed using the inverse-variance weighted (IVW) 
method wherein SNP associations with the outcome (breast 
cancer) were regressed on SNP associations with the expo-
sure (BW) using a linear model weighted by the inverse of 
the variance of SNP associations with the outcome [38]. 
This approach to MR analysis as applied to summary genetic 
association statistics is equivalent to standard two-stage least 
squares regression MR using individual-level genetic data 
[38]. The standard error of the IVW effect was estimated by 
a multiplicative random-effects model.
The IVW method assumes that the IV as a whole 
satisfies the MR assumptions or that all SNPs in the IV 
constitute valid instruments. Because the validity of this 
assumption is difficult to test empirically, four additional 
MR methods were also used as sensitivity analyses to 
assess the robustness of the result from the primary analy-
sis under alternative assumptions: weighted median func-
tion [39], weighted mode function [40], MR-Egger regres-
sion [41], and penalised robust IVW regression [42]. The 
weighted median function provides a valid result under the 
assumption that over 50% of the weight in the IV model 
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comes from SNPs that satisfy the MR assumptions. The 
weighted mode function is valid if the largest number of 
SNPs with similar individual Wald ratios [beta(outcome)/
beta(exposure)] are valid instruments even if other SNPs 
in the IV do not meet the requirements for causal infer-
ence using MR. The weighted effect in these functions 
is derived from the inverse of the standard error of the 
Wald ratio for each SNP. Penalised robust IVW uses robust 
regression in place of standard linear regression-based 
IVW, with a penalty on the contribution to the analysis 
of SNPs with outlying Wald ratios. MR-Egger regression 
allows for horizontal pleiotropic effects, i.e., the associa-
tion between SNPs in the IV and other traits that may 
affect the outcome via pathways independent of the expo-
sure. It assumes that such pleiotropy is not correlated with 
SNP-exposure associations and under this assumption, the 
MR-Egger result is valid even if all SNPs in the IV are 
invalid instruments for MR due to their pleiotropic asso-
ciations. Further, the MR-Egger regression intercept pro-
vides an estimate of the average pleiotropic effect over all 
SNPs in the IV and if this differs from zero, it indicates the 
presence of horizontal pleiotropy [41]. The null hypothesis 
that this intercept did not differ significantly from zero 
was also tested. The R package MendelianRandomization 
(v0.2.2) was used for the penalised robust IVW MR analy-
sis and TwoSampleMR for all other MR methods [42, 43].
Pleiotropy was also assessed by calculating Cochran’s Q 
as a measure of between-instrument heterogeneity using the 
Wald ratios for each SNP in the 41-SNP IV [44]. To identify 
specific SNPs in this IV that contributed to observed het-
erogeneity and were potentially pleiotropic, four steps were 
taken. First, SNPs were removed iteratively from the 41-SNP 
IV until Cochran’s Q test was no longer significant at the 
P < 0.05 level using the stepwise downward “model selec-
tion” procedure implemented in the R package gtx (v0.0.8). 
Second, Cook’s distance (with a threshold of 4/number of 
SNPs in the IV) was used to identify SNPs in the 41-SNP IV 
with a disproportionate influence on the primary IVW model 
[45, 46]. Third, leave-one-out permutation analysis was per-
formed, i.e., each SNP was sequentially removed from the 
41-SNP IV and the primary IVW MR analysis repeated. 
Fourth, studentised residuals (with a threshold of ± 2) were 
used to identify outlier SNPs in the IVW model [46]. The 
effect of pleiotropy was further investigated by applying the 
standard IVW approach to a 24-SNP IV created by remov-
ing all BW loci associated with at least one of the seven 
breast cancer risk factors at P < 9.2 × 10−4 (after Bonferroni 
correction for examining pleiotropic associations at 54 BW 
loci). As with the main 41-SNP IV, all 24 SNPs were BW-
associated lead SNPs (the SNPs are highlighted in Supple-
mentary Table 2). Finally, we note that we did also test using 
the IVW method the full 59-SNP IV (i.e., all SNPs listed 
in Supplementary Table 2), which constituted all known 
BW-associated lead SNPs with matched breast cancer data 
available regardless of their pleiotropic associations.
The proportions of variance of BW explained by 
the 41-SNP and 59-SNP IVs were estimated using the 
“steiger.R” function (https ://rdrr.io/githu b/MRCIE U/
TwoSa mpleM R/src/R/steig er.R) and a priori power to 
detect an association at a significance level of 0.05 was 
calculated using an online tool (https ://sb452 .shiny apps.io/
power ) [47]. The strength of the 41-SNP and 59-SNP IVs 
was also evaluated using the F-statistic [48], with F < 10 
considered as an indicator of a ‘weak’ instrument [49]. 
All statistical tests were 2-sided and P < 0.05 was con-
sidered statistically significant unless otherwise specified. 
Each analysis was repeated for the three outcomes: overall 
breast cancer risk, ER-positive breast cancer risk, and ER-
negative breast cancer risk.
Multivariable Mendelian randomisation
Multivariable MR (MVMR) represents an alternative 
strategy for conducting an MR analysis using an IV that 
contains SNPs which in addition to their established asso-
ciation with the exposure of interest are also associated 
with other known risk factors for the outcome [50, 51]. 
MVMR allows for the inclusion of such SNPs in the IV 
by adjusting for their associations with these risk factors. 
MVMR analysis was performed by regressing SNP asso-
ciations with breast cancer on SNP associations with BW, 
birth length, adult height, adult BMI, age at menarche, 
and age at menopause in a single regression model. This 
model thus helped estimate the effect of BW on breast 
cancer independent of the effects of these other factors on 
breast cancer [50, 51]. Like its univariable counterpart, an 
inverse-variance weighted linear regression model with 
multiplicative random effects was used for MVMR. The 
IV used for MVMR contained 49 SNPs (Supplementary 
Table 4). As described under “Data harmonisation”, 26 
SNPs were BW-associated lead SNPs and 23 were proxy 
SNPs strongly correlated (r2 > 0.8) with the BW-associ-
ated lead SNPs at their respective BW loci (five additional 
proxy SNPs with r2 > 0.6 but r2 < 0.8 were omitted from 
the MVMR IV; Supplementary Tables 3 and 4). Since beta 
coefficients were not available for SNP associations with 
age at first birth and number of children ever born, these 
variables were not included in the MVMR model. How-
ever, none of the 49 SNPs were associated at P < 5 × 10−8 
with these two variables (Supplementary Tables 3 and 
4). Multivariable extensions of MR-Egger regression 
and the MR-Egger intercept test were also applied to this 
49-SNP IV [52]. Each analysis was repeated for the three 
outcomes: overall breast cancer risk, ER-positive breast 
cancer risk, and ER-negative breast cancer risk.
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Statistical power
The 41-SNP IV explained 1.3% of the variance of BW (F-sta-
tistic = 46.1) and had over 80% power to detect 11% increase 
(or decrease) in overall breast cancer risk in the univariable 
MR analysis (odds ratios (ORs) of 0.89 or 1.11 per 1-standard 
deviation (SD; 500 g) higher BW). The 59-SNP IV explained 
2% of the variance of BW (F-statistic = 49.7) and had over 
80% power to detect 9% increase (or decrease) in overall breast 
cancer risk in the univariable MR analysis (ORs of 0.91 or 1.09 
per 1-SD higher BW). For comparison, the largest observa-
tional investigation of the association between BW and breast 
cancer risk [7], a pooled analysis of individual participant 
data from 32 studies (22,058 breast cancer cases and 604,854 
non-cases) identified 6% increase in breast cancer risk or a 
pooled relative risk per 1-SD (500 g) higher BW of 1.06 [95% 
confidence interval (CI) 1.02–1.09]. The 41-SNP and 59-SNP 
genetic instruments had 35% and 50% power, respectively, to 
detect an OR of 1.06. Power calculations for the corresponding 
univariable (IVW) MR analyses specific to ER-positive and 
ER-negative breast cancer risks are provided in Supplemen-
tary Table 5. We also confirmed the power of the 41-SNP IV 
to detect an association between lower BW and increased risk 
of type 2 diabetes (T2D) in later life using summary genome-
wide association meta-analysis statistics from 26,676 T2D 
cases and 132,532 controls (Supplementary Table 1; IVW 
OR = 1.93; 95% CI 1.20–3.08; P = 0.006) [53]. This associa-
tion has been previously identified in two MR studies [54, 55].
Results
Associations between individual SNPs and breast 
cancer
Of the 59 BW-associated lead SNPs, 18 were associated with 
overall breast cancer risk at P < 0.05, six after Bonferroni 
correction for testing 59 SNPs (P < 8 × 10−4), and two at 
P < 5 × 10−8 (Supplementary Table 2). Of the 18 SNPs asso-
ciated with overall breast cancer risk at P < 0.05, the direc-
tion of association with BW was inverse for 13 SNPs (i.e., 
the allele that increased BW was protective for breast can-
cer). Notably, this direction of association is contrary to that 
identified by observational studies which suggest that higher 
BW is associated with increased breast cancer risk in later 
life. The 13 SNPs included both genome-wide significant 
overall breast cancer risk SNPs, rs2229742 (encoding mis-
sense mutation R448G in NRIP1) and rs1101081 (intronic 
SNP in ESR1). The 18 SNPs represented a six-fold enrich-
ment over the number of associations with breast cancer at 
P < 0.05 that were expected by chance alone. Associations 
between individual SNPs and ER-positive and ER-negative 
breast cancer are also provided in Supplementary Table 2.
Univariable Mendelian randomisation
MR analysis of the 41-SNP IV using the IVW method 
yielded an OR of 0.86 (95% CI 0.73–1.01; P = 0.06) for 
overall breast cancer per 1-SD (500 g) higher BW (Fig. 2 
a). These estimates were consistent in direction with the 
results of the weighted median, weighted mode, MR-
Egger, and penalised robust IVW sensitivity analyses 
[Fig. 2a and Supplementary Figure 1(a)]. The MR-Egger 
intercept test (P = 0.26) suggested absence of strong direc-
tional horizontal pleiotropy (i.e., effects of the 41-SNP IV 
on breast cancer via a pathway that arises proximal to or 
upstream of BW).
Testing for heterogeneity between SNPs in the IV using 
Cochran’s Q indicated significant heterogeneity in Wald 
ratios for individual SNPs in the IV (P = 3.6 × 10−16 for 
overall breast cancer; P = 6.4 × 10−11 for ER-positive breast 
cancer; P = 6.5 × 10−5 for ER-negative breast cancer), sug-
gesting that some of the 41 SNPs may exert disproportion-
ately large effects on breast cancer risk some of which might 
act via pathways other than BW. Leave-one-out permuta-
tion [Supplementary Figure 1 (b)], Cook’s distance, and 
stepwise downward “model selection” consistently identi-
fied five SNPs with large effects on breast cancer that had 
an undue influence on the overall results (Supplementary 
Table 6). The stepwise downward approach suggested that 
an additional (sixth) SNP also contributed to the observed 
heterogeneity, while studentised residuals identified three of 
the five SNPs as outliers (Supplementary Table 6). Remov-
ing the five SNPs and repeating the standard IVW method 
using the remaining 36 SNPs that represented a more homo-
geneous genetic instrument for BW yielded an OR of 0.92 
(95% CI 0.83–1.02; P = 0.11; Cochran’s Q = 49.57 and its 
associated P = 0.052). Further reducing the potential impact 
of pleiotropy at the cost of losing power by using the 24-SNP 
IV constructed after removal of all SNPs associated at 
P < 9.2 × 10−4 (instead of P < 5 × 10−8) with at least one of 
seven putative breast cancer risk factors did not significantly 
change the primary IVW MR result (Fig. 2a). Conversely, 
using the full 59-SNP IV to leverage maximum statistical 
power did not meaningfully alter the primary result either 
(Fig. 2a). Results for each corresponding analysis specific 
to ER-positive and ER-negative breast cancer are presented 
in Fig. 2b, c, Supplementary Figures 1 (c) to (f), and Sup-
plementary Table 6. Across all analyses point estimates of 
the OR were either null or indicated an inverse relationship 
between BW and adult breast cancer, again contrary to the 
observational literature.
Multivariable Mendelian randomisation
MR analysis of the 49-SNP IV for BW simultaneously 
adjusting for the genetically predicted effects of these 
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SNPs on birth length, adult height, adult BMI, age at 
menarche, and age at menopause using the weighted 
regression-based framework provided estimates for the 
association between BW and overall breast cancer risk that 
were consistent with the univariable results (OR = 0.82; 
95% CI 0.60–1.11; P = 0.20; Fig. 2a). The estimates from 
the multivariable extension of MR-Egger were similar 
(Fig. 2a) and the corresponding MR-Egger intercept test 
was not significant (P = 0.89 for overall breast cancer; 
P = 0.75 for ER-positive breast cancer; P = 0.99 for ER-
negative breast cancer). Results specific to ER-positive 
and ER-negative breast cancer are presented in Fig. 2b, c.
Discussion
We conducted a two-sample MR study using summary sta-
tistics from the largest genome-wide association meta-analy-
ses data sets currently available for BW and for breast cancer 
susceptibility in adults. Our study provides no evidence to 
support the association between higher weight at birth and 
an increased risk of developing breast cancer in later life 
that was previously reported in observational studies. In 
fact, we found that higher genetically-predicted BW might, 
if anything, be associated with reduced breast cancer risk. 
Our results were robust to the application of different MR 
approaches, each with its own distinct set of assumptions.
A few observational studies suggest that the association 
between higher BW and increased future breast cancer risk 
is confined to premenopausal women but combined analyses 
of these studies show that this association does not differ 
by menopausal status [7, 8]. ER-negative breast cancers are 
more common in premenopausal women and our MR study 
did not reveal any differences in the (lack of) association 
between genetically-predicted BW and breast cancer risk by 
ER-status (Fig. 2b, c). Some of the epidemiological litera-
ture also suggests that longer birth length may be a stronger 
risk factor for adult breast cancer than, and independently of, 
higher BW [7]. Birth length is highly correlated with BW and 
harder to measure as a phenotype making its measurement 
prone to error. Only two SNP-associations (rs905938 and 
Fig. 2  Forest plots of odds ratios (ORs) and 95% confidence intervals 
(CIs) for the association between birth weight (BW) and (a) overall 
breast cancer, (b) estrogen receptor (ER)-positive breast cancer, and 
(c) ER-negative breast cancer based on the different Mendelian ran-
domisation approaches used in this study. Multivariable (MV) meth-
ods used the 49-SNP instrumental variable (IV) and all other meth-
ods, unless otherwise specified in the plots, used the 41-SNP IV. IVW 
indicates inverse-variance weighted regression, SD is standard devia-
tion, and “no het” refers to no significant between-instrument hetero-
geneity at P < 0.05 based on Cochran’s Q
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rs724577) with birth length have been identified at genome-
wide significance (P < 5 × 10−8) to date [31]. Both SNPs were 
also associated at P < 5 × 10−8 with BW and at P < 6 × 10−8 
with adult height in the data sets that we used (Supplemen-
tary Table 3; the birth length-increasing alleles also increased 
BW and adult height). We did not use MR to assess the inde-
pendent effect of birth length on adult breast cancer risk due 
to the availability of just two SNPs both of which are strongly 
pleiotropic and the consequent potential for unreliable esti-
mates with such a genetic instrument. We could not include 
age at first birth and number of children ever born in our 
multivariable MR analyses since the publicly-available sum-
mary genetic association statistics for these two phenotypes 
were restricted to P-values only. However, only two BW 
SNPs were associated with age at first birth (rs12823128 and 
rs7742369) and no SNP was associated with number of chil-
dren ever born at P < 9.2 × 10−4 (after Bonferroni correction 
for testing associations at 54 SNPs; Supplementary Table 3). 
We removed these two SNPs in constructing our 24-SNP IV 
for univariable MR analysis, which yielded estimates consist-
ent with the other univariable and multivariable MR analyses. 
Given this result and the lack of strong associations between 
the other birth weight SNPs and age at first birth and number 
of children ever born, not being able to adjust for these two 
putative breast cancer risk factors in our multivariable MR 
is highly unlikely to have substantially altered the overall 
conclusion from our MR study.
While our point estimates for the effect of BW on breast 
cancer risk never reached statistical significance at the 
P < 0.05 level, they did uniformly indicate that the effect 
(if any) of higher BW on adult breast cancer might be pro-
tective (Fig. 2). A possible protective effect of higher BW 
on adult breast cancer risk would be consistent with MR 
findings that genetically-predicted adult BMI is associated 
with reduction in breast cancer risk but, crucially, opposite 
in direction to estimates from combined analyses of obser-
vational studies investigating the BW-breast cancer link 
[7, 8, 56]. MR analysis has previously identified an asso-
ciation between higher BW and elevated BMI in adulthood 
and genome-wide genetic correlation analysis carried out 
as part of the Horikoshi et al. study also supported a posi-
tive correlation between BW and adult BMI [29, 55]. Our 
MR results, however, reflect the effects of the genetic IV 
for BW on breast cancer independent of the effects of the 
IV on adult BMI since we removed adult BMI-associated 
SNPs from the IV before univariable analyses and adjusted 
for SNP associations with adult BMI as a covariate in mul-
tivariable analyses.
There are three aspects of the genome-wide associa-
tion meta-analysis by Horikoshi et al. [29] from which we 
obtained the BW lead SNPs to construct the IVs used in 
our MR study that are worth noting here. First, our genetic 
IV with maximum power (59-SNP IV) explained only 2% 
of the variance of BW and therefore we were relatively 
underpowered to detect an odds ratio of 1.06 (or an even 
smaller effect) at the 5% significance level. Second, all 
autosomal SNPs genotyped on the array used by the UK 
Biobank (which was the largest sub-study in the genome-
wide association meta-analysis by Horkioshi et al.) together 
explained approximately 15% of the variance of BW. Thus, 
it is likely that factors other than genetics account for the 
majority of the variance of BW. Third, the Horikoshi et al. 
study excluded individuals with extremes of BW (for the 
UK Biobank, which contributed nearly half the European 
sample, this was defined as < 2500 g or > 4000 g). Thus, the 
genetic IV we used may not adequately capture common 
genetic variants that only specifically affect the extremes of 
BW (i.e., only if such variants exist). This is relevant because 
in combined analyses of observational studies, statistically 
significant increases in adult breast cancer risk are only iden-
tified when comparing BW ≥ 4000 g as an exposure to BW 
with 3000–3499 g or < 2500 g as the reference categories [7, 
8]. However, it is highly unlikely that the genetic architecture 
of extreme BW completely differs from the genetic architec-
ture of BW in general and therefore, our genetic IV likely 
predicts BW to some degree even at the extremes.
It has been suggested that insulin-like growth factor (IGF) 
signalling is one potential pathway linking increased BW 
to breast cancer risk in later life [3]. Haematopoietic stem 
or progenitor cells in neonatal cord blood have been used 
as a proxy for the size of the fetal mammary stem cell pool 
since the latter is impossible to measure. The level of hae-
matopoietic stem cells in cord blood is positively correlated 
with IGF-1 levels in cord blood and with BW [5, 57]. Cord 
blood IGF-1 concentrations have been found to be higher 
among Caucasian neonates than Chinese neonates and it has 
been hypothesised that these differences may be responsible, 
in part, for the differences in breast cancer risks observed 
between these two populations [58, 59]. Lead SNPs near 
IGF1 (rs7964361) and IGF1R (rs7402982) that encode 
IGF-1 and its receptor, respectively, were associated with 
birth weight at P < 5 × 10−8 and with adult height in women 
at P < 6 × 10−4 (Supplementary Tables 2 and 3). However, 
neither SNP was associated with overall or ER-positive or 
ER-negative breast cancer risks at P < 0.05 although the 
alleles that increased BW also conferred breast cancer risk 
(Supplementary Table 2; IVW MR analysis P = 0.59 for 
overall breast cancer risk when using just these two SNPs as 
an IV for BW). Thus, while there is an association between 
SNPs in the core IGF-1 signalling genes and BW, our data 
do not provide any evidence that higher BW as predicted by 
these two IGF pathway SNPs is associated with adult breast 
cancer risk. While data on the association between BW and 
breast cancer risk in non-European populations is scarce, it 
is also worth noting here that a small study from China failed 
to show any association [23].
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In conclusion, the association between higher BW and 
increased risk of developing breast cancer in adulthood has 
been identified in several observational studies published 
over the last three decades. Revisiting this association using 
a comprehensive set of recently-developed MR methods and 
the largest available genomic data sets provides no evidence 
to suggest that genetically-predicted higher BW is associated 
with increased breast cancer risk in adult life. A key unan-
swered question is whether the association between higher 
BW and increased breast cancer risk seen in observational 
studies is largely due to the BW-increasing effect of non-
genetic factors such as maternal hormones and nutrition and 
we are unable to rule out an association between the non-
genetically-determined component of BW and breast cancer.
Acknowledgements This work builds on multiple, publicly available 
data sets. Data on birth weight and birth length were obtained from the 
Early Growth Genetics (EGG) Consortium. Data on adult height and 
adult body mass index were obtained from the Genetic Investigation of 
ANthropometric Traits (GIANT) Consortium. Data on age at menarche 
and age at menopause were obtained from the Reproductive Genetics 
(ReproGen) Consortium. Data on age at first birth and number of chil-
dren ever born were obtained from the Social Science Genetic Associa-
tion Consortium (SSGAC). Data on type 2 diabetes were obtained from 
the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) 
Consortium. Data on breast cancer were obtained from the Breast Can-
cer Association Consortium (BCAC).
Funding Funding was provided by Cancer Research UK (grant number 
C490/A16561 to Paul D. P. Pharoah).
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict of 
interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Trichopoulos D. Hypothesis: does breast cancer originate in utero? 
Lancet. 1990;335:939–40.
 2. Trichopoulos D. Intrauterine environment, mammary gland mass 
and breast cancer risk. Breast Cancer Res. 2003;5:42–4.
 3. Ginestier C, Wicha MS. Mammary stem cell number as a deter-
minate of breast cancer risk. Breast Cancer Res. 2007;9:109.
 4. Trichopoulos D, Lagiou P, Adami H-O. Towards an integrated 
model for breast cancer etiology: the crucial role of the num-
ber of mammary tissue-specific stem cells. Breast Cancer Res. 
2005;7:13–7.
 5. Strohsnitter WC, Savarese TM, Low HP, Chelmow DP, Lagiou 
P, Lambe M, et al. Correlation of umbilical cord blood hae-
matopoietic stem and progenitor cell levels with birth weight: 
implications for a prenatal influence on cancer risk. Br J Cancer. 
2008;98:660–3.
 6. Qiu L, Low HP, Chang C-I, Strohsnitter WC, Anderson M, 
Edmiston K, et al. Novel measurements of mammary stem cells 
in human umbilical cord blood as prospective predictors of breast 
cancer susceptibility in later life. Ann Oncol. 2012;23:245–50.
 7. Silva I dos S, De Stavola B, McCormack V. Collaborative Group 
on Pre-Natal Risk Factors and Subsequent Risk of Breast Cancer. 
Birth size and breast cancer risk: re-analysis of individual partici-
pant data from 32 studies. PLoS Med. 2008;5:e193.
 8. Michels KB, Xue F. Role of birthweight in the etiology of breast 
cancer. Int J Cancer. 2006;119:2007–25.
 9. Kaijser M, Akre O, Cnattingius S, Ekbom A. Preterm birth, birth 
weight, and subsequent risk of female breast cancer. Br J Cancer. 
2003;89:1664–6.
 10. Ahlgren M, Melbye M, Wohlfahrt J, Sørensen TIA. Growth 
patterns and the risk of breast cancer in women. N Engl J Med. 
2004;351:1619–26.
 11. Vatten LJ, Nilsen TIL, Tretli S, Trichopoulos D, Romundstad PR. 
Size at birth and risk of breast cancer: prospective population-
based study. Int J Cancer. 2005;114:461–4.
 12. Michels KB, Trichopoulos D, Robins JM, Rosner BA, Manson 
JE, Hunter DJ, et al. Birthweight as a risk factor for breast cancer. 
Lancet. 1996;348:1542–6.
 13. Sanderson M, Williams MA, Malone KE, Stanford JL, Emanuel 
I, White E, et al. Perinatal factors and risk of breast cancer. Epi-
demiology. 1996;7:34–7.
 14. Innes K, Byers T, Schymura M. Birth characteristics and subse-
quent risk for breast cancer in very young women. Am J Epide-
miol. 2000;152:1121–8.
 15. Mellemkjaer L, Olsen ML, Sørensen HT, Thulstrup AM, Olsen 
J, Olsen JH. Birth weight and risk of early-onset breast cancer 
(Denmark). Cancer Causes Control CCC. 2003;14:61–4.
 16. Kaijser M, Lichtenstein P, Granath F, Erlandsson G, Cnattingius 
S, Ekbom A. In utero exposures and breast cancer: a study of 
opposite-sexed twins. J Natl Cancer Inst. 2001;93:60–2.
 17. Michels KB, Xue F, Terry KL, Willett WC. Longitudinal study 
of birthweight and the incidence of breast cancer in adulthood. 
Carcinogenesis. 2006;27:2464–8.
 18. Vatten LJ, Maehle BO, Lund Nilsen TI, Tretli S, Hsieh CC, 
Trichopoulos D, et al. Birth weight as a predictor of breast cancer: 
a case–control study in Norway. Br J Cancer. 2002;86:89–91.
 19. McCormack VA, dos Santos Silva I, Koupil I, Leon DA, 
Lithell HO. Birth characteristics and adult cancer incidence: 
Swedish cohort of over 11,000 men and women. Int J Cancer. 
2005;115:611–7.
 20. dos Santos Silva I, De Stavola BL, Hardy RJ, Kuh DJ, McCor-
mack VA, Wadsworth MEJ. Is the association of birth weight 
with premenopausal breast cancer risk mediated through child-
hood growth? Br J Cancer. 2004;91:519–24.
 21. Ekbom A, Hsieh CC, Lipworth L, Adami HQ, Trichopoulos D. 
Intrauterine environment and breast cancer risk in women: a pop-
ulation-based study. J Natl Cancer Inst. 1997;89:71–6.
 22. Sanderson M, Williams MA, Daling JR, Holt VL, Malone KE, 
Self SG, et al. Maternal factors and breast cancer risk among 
young women. Paediatr Perinat Epidemiol. 1998;12:397–407.
 23. Sanderson M, Shu XO, Jin F, Dai Q, Ruan Z, Gao Y-T, et al. 
Weight at birth and adolescence and premenopausal breast cancer 
risk in a low-risk population. Br J Cancer. 2002;86:84–8.
 24. Troisi R, Hatch EE, Titus-Ernstoff L, Palmer JR, Hyer M, 
Strohsnitter WC, et al. Birth weight and breast cancer risk. Br J 
Cancer. 2006;94:1734–7.
 25. Andersen ZJ, Baker JL, Bihrmann K, Vejborg I, Sørensen TIA, 
Lynge E. Birth weight, childhood body mass index, and height in 
relation to mammographic density and breast cancer: a register-
based cohort study. Breast Cancer Res. 2014;16:R4.
The association between weight at birth and breast cancer risk revisited using Mendelian…
1 3
 26. Spracklen CN, Wallace RB, Sealy-Jefferson S, Robinson JG, 
Freudenheim JL, Wellons MF, et al. Birth weight and subsequent 
risk of cancer. Cancer Epidemiol. 2014;38:538–43.
 27. Titus-Ernstoff L, Egan KM, Newcomb PA, Ding J, Trentham-
Dietz A, Greenberg ER, et al. Early life factors in relation to breast 
cancer risk in postmenopausal women. Cancer Epidemiol Bio-
markers Prev. 2002;11:207–10.
 28. Hodgson ME, Newman B, Millikan RC. Birthweight, parental age, 
birth order and breast cancer risk in African-American and white 
women: a population-based case-control study. Breast Cancer Res. 
2004;6:R656–67.
 29. Horikoshi M, Beaumont RN, Day FR, Warrington NM, Kooi-
jman MN, Fernandez-Tajes J, et al. Genome-wide associations 
for birth weight and correlations with adult disease. Nature. 
2016;538:248–52.
 30. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, 
et al. Association analysis identifies 65 new breast cancer risk loci. 
Nature. 2017;551:92–4.
 31. van der Valk RJP, Kreiner-Møller E, Kooijman MN, Guxens M, 
Stergiakouli E, Sääf A, et al. A novel common variant in DCST2 
is associated with length in early life and height in adulthood. 
Hum Mol Genet. 2015;24:1155–68.
 32. Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson 
S, et al. Defining the role of common variation in the genomic 
and biological architecture of adult human height. Nat Genet. 
2014;46:1173–86.
 33. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, 
et al. Genetic studies of body mass index yield new insights for 
obesity biology. Nature. 2015;518:197–206.
 34. Perry JR, Day F, Elks CE, Sulem P, Thompson DJ, Ferreira T, 
et al. Parent-of-origin-specific allelic associations among 106 
genomic loci for age at menarche. Nature. 2014;514:92–7.
 35. Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, 
Chasman DI, et al. Large-scale genomic analyses link reproduc-
tive aging to hypothalamic signaling, breast cancer susceptibility 
and BRCA1-mediated DNA repair. Nat Genet. 2015;47:1294–303.
 36. Barban N, Jansen R, de Vlaming R, Vaez A, Mandemakers JJ, 
Tropf FC, et al. Genome-wide analysis identifies 12 loci influenc-
ing human reproductive behavior. Nat Genet. 2016;48:1462–72.
 37. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O’Donnell 
CJ, de Bakker PIW. SNAP: a web-based tool for identification 
and annotation of proxy SNPs using HapMap. Bioinformatics. 
2008;24:2938–9.
 38. Burgess S, Butterworth A, Thompson SG. Mendelian randomi-
zation analysis with multiple genetic variants using summarized 
data. Genet Epidemiol. 2013;37:658–65.
 39. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent 
estimation in mendelian randomization with some invalid instru-
ments using a weighted median estimator. Genet Epidemiol. 
2016;40:304–14.
 40. Hartwig FP, Davey Smith G, Bowden J. Robust inference in sum-
mary data Mendelian randomization via the zero modal pleiotropy 
assumption. Int J Epidemiol. 2017;46:1985–98.
 41. Bowden J, Davey Smith G, Burgess S. Mendelian randomiza-
tion with invalid instruments: effect estimation and bias detection 
through Egger regression. Int J Epidemiol. 2015;44:512–25.
 42. Yavorska OO, Burgess S. MendelianRandomization: an R package 
for performing Mendelian randomization analyses using summa-
rized data. Int J Epidemiol. 2017;46:1734–9.
 43. Hemani G, Zheng J, Wade KH, Laurin C, Elsworth B, Burgess S, 
et al. MR-Base: a platform for systematic causal inference across 
the phenome using billions of genetic associations. 2016 [cited 
2018 Jan 30]. http://biorx iv.org/looku p/doi/10.1101/07897 2.
 44. Greco MFD, Minelli C, Sheehan NA, Thompson JR. Detecting 
pleiotropy in Mendelian randomisation studies with summary data 
and a continuous outcome. Stat Med. 2015;34:2926–40.
 45. Cook RD. Detection of influential observation in linear regression. 
Technometrics. 1977;19:15.
 46. Corbin LJ, Richmond RC, Wade KH, Burgess S, Bowden J, Smith 
GD, et al. BMI as a modifiable risk factor for type 2 diabetes: 
refining and understanding causal estimates using Mendelian ran-
domization. Diabetes. 2016;65:3002–7.
 47. Burgess S. Sample size and power calculations in Mendelian 
randomization with a single instrumental variable and a binary 
outcome. Int J Epidemiol. 2014;43:922–9.
 48. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, 
Timpson NJ, et al. Using multiple genetic variants as instrumen-
tal variables for modifiable risk factors. Stat Methods Med Res. 
2012;21:223–42.
 49. Swerdlow DI, Kuchenbaecker KB, Shah S, Sofat R, Holmes MV, 
White J, et al. Selecting instruments for Mendelian randomization 
in the wake of genome-wide association studies. Int J Epidemiol. 
2016;45:1600–16.
 50. Burgess S, Thompson SG. Multivariable Mendelian randomiza-
tion: the use of pleiotropic genetic variants to estimate causal 
effects. Am J Epidemiol. 2015;181:251–60.
 51. Burgess S, Dudbridge F, Thompson SG. Re: “Multivariable Men-
delian randomization: the use of pleiotropic genetic variants to 
estimate causal effects”. Am J Epidemiol. 2015;181:290–1.
 52. Rees JMB, Wood AM, Burgess S. Extending the MR-Egger 
method for multivariable Mendelian randomization to cor-
rect for both measured and unmeasured pleiotropy. Stat Med. 
2017;36:4705–18.
 53. Scott RA, Scott LJ, Mägi R, Marullo L, Gaulton KJ, Kaakinen 
M, et al. An expanded genome-wide association study of type 2 
diabetes in Europeans. Diabetes. 2017;66:2888–902.
 54. Wang T, Huang T, Li Y, Zheng Y, Manson JE, Hu FB, et al. Low 
birthweight and risk of type 2 diabetes: a Mendelian randomisa-
tion study. Diabetologia. 2016;59:1920–7.
 55. Zanetti D, Tikkanen E, Gustafsson S, Priest JR, Burgess S, Ingels-
son E. Birthweight, type 2 diabetes mellitus, and cardiovascular 
disease: addressing the Barker hypothesis With Mendelian rand-
omization. Circ Genomic Precis Med. 2018;11:e002054.
 56. Guo Y, Warren Andersen S, Shu X-O, Michailidou K, Bolla 
MK, Wang Q, et  al. Genetically predicted body mass index 
and breast cancer risk: Mendelian randomization analyses of 
data from 145,000 women of European descent. PLoS Med. 
2016;13:e1002105.
 57. Savarese TM, Strohsnitter WC, Low HP, Liu Q, Baik I, Oku-
licz W, et al. Correlation of umbilical cord blood hormones and 
growth factors with stem cell potential: implications for the 
prenatal origin of breast cancer hypothesis. Breast Cancer Res. 
2007;9:R29.
 58. Lagiou P, Hsieh CC, Lipworth L, Samoli E, Okulicz W, Troisi R, 
et al. Insulin-like growth factor levels in cord blood, birth weight 
and breast cancer risk. Br J Cancer. 2009;100:1794–8.
 59. Lagiou P, Samoli E, Hsieh C-C, Lagiou A, Xu B, Yu G-P, et al. 
Maternal and cord blood hormones in relation to birth size. Eur J 
Epidemiol. 2014;29:343–51.
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
 S. P. Kar et al.
1 3
Affiliations
Siddhartha P. Kar1,30  · Irene L. Andrulis2,3 · Hermann Brenner4,5,6 · Stephen Burgess1,7 · Jenny Chang‑Claude8,9 · 
Daniel Considine1 · Thilo Dörk10 · Dafydd Gareth R. Evans11 · Manuela Gago‑Domínguez12,13 · Graham G. Giles14,15 · 
Mikael Hartman16,17 · Dezheng Huo18 · Rudolf Kaaks8 · Jingmei Li19 · Artitaya Lophatananon20 · Sara Margolin21 · 
Roger L. Milne14,15 · Kenneth R. Muir20 · Håkan Olsson22 · Kevin Punie23 · Paolo Radice24 · Jacques Simard25 · 
Rulla M. Tamimi26,27 · Els Van Nieuwenhuysen23 · Camilla Wendt21 · Wei Zheng28 · Paul D. P. Pharoah1,29
1 Department of Public Health and Primary Care, University 
of Cambridge, Cambridge, UK
2 Fred A. Litwin Center for Cancer Genetics, 
Lunenfeld-Tanenbaum Research Institute of Mount Sinai 
Hospital, Toronto, ON, Canada
3 Department of Molecular Genetics, University of Toronto, 
Toronto, ON, Canada
4 Division of Clinical Epidemiology and Ageing Research, 
German Cancer Research Center (DKFZ), Heidelberg, 
Germany
5 German Cancer Consortium (DKTK), German Cancer 
Research Center (DKFZ), Heidelberg, Germany
6 Division of Preventive Oncology, German Cancer Research 
Center (DKFZ) and National Center for Tumor Diseases 
(NCT), Heidelberg, Germany
7 MRC Biostatistics Unit, University of Cambridge, 
Cambridge, UK
8 Division of Cancer Epidemiology, German Cancer Research 
Center (DKFZ), Heidelberg, Germany
9 Cancer Epidemiology, University Medical Center 
Hamburg-Eppendorf, University Cancer Center Hamburg 
(UCCH), Hamburg, Germany
10 Gynaecology Research Unit, Hannover Medical School, 
Hannover, Germany
11 Division of Evolution and Genomic Sciences, School 
of Biological Sciences, Faculty of Biology, Medicine, 
and Health, University of Manchester, Manchester Academic 
Health Science Centre, Manchester, UK
12 Genomic Medicine Group, Galician Foundation of Genomic 
Medicine, Complejo Hospitalario Universitario de 
Santiago, Servicio Galego de Saude (SERGAS), Instituto de 
Investigación Sanitaria de Santiago de Compostela (IDIS), 
Santiago De Compostela, Spain
13 Moores Cancer Center, University of California San Diego, 
La Jolla, CA, USA
14 Cancer Epidemiology and Intelligence Division, Cancer 
Council Victoria, Melbourne, VIC, Australia
15 Center for Epidemiology and Biostatistics, Melbourne School 
of Population and Global Health, University of Melbourne, 
Parkville, VIC, Australia
16 Saw Swee Hock School of Public Health, National University 
of Singapore, Singapore, Singapore
17 Department of Surgery, National University of Singapore, 
Singapore, Singapore
18 Department of Public Health Sciences, University 
of Chicago, Chicago, IL, USA
19 Human Genetics, Genome Institute of Singapore, Singapore, 
Singapore
20 Division of Population Health, Health Services Research 
and Primary Care, School of Health Sciences, Faculty 
of Biology, Medicine and Health, University of Manchester, 
Manchester, UK
21 Department of Oncology, Södersjukhuset and Department 
of Clinical Science and Education, Södersjukhuset, 
Karolinska Institutet, Stockholm, Sweden
22 Department of Cancer Epidemiology, Clinical Sciences, 
Lund University, Lund, Sweden
23 Department of Oncology, Leuven Multidisciplinary Breast 
Centre, University Hospital Leuven, KU Leuven, Louvain, 
Belgium
24 Unit of Molecular Bases of Genetic Risk and Genetic 
Testing, Department of Research, Fondazione IRCCS 
(Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto 
Nazionale dei Tumori (INT), Milan, Italy
25 Genomics Center, Centre Hospitalier Universitaire de 
Québec - Université Laval Research Center, Quebec City, 
QC, Canada
26 Department of Epidemiology, Harvard T.H. Chan School 
of Public Health, Boston, MA, USA
27 Channing Division of Network Medicine, Department 
of Medicine, Brigham and Women’s Hospital and Harvard 
Medical School, Boston, MA, USA
28 Division of Epidemiology, Department of Medicine, 
Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer 
Center, Vanderbilt University School of Medicine, Nashville, 
TN, USA
29 Department of Oncology, University of Cambridge, 
Cambridge, UK
30 Homerton College, Hills Road, Cambridge CB2 8PH, UK
